Organon/Medarex Expand UltiMab Antibody Agreement To Focus On Novel Target
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms will codevelop Medarex-identified target, interim CEO Lerner tells “The Pink Sheet” DAILY.
You may also be interested in...
Medarex/Centocor Extend Long-Term Antibody Development Relationship
J&J subsidiary has generated antibodies now in the clinic using Medarex’s UltiMAb technology, Medarex tells “The Pink Sheet” DAILY.
Medarex/Centocor Extend Long-Term Antibody Development Relationship
J&J subsidiary has generated antibodies now in the clinic using Medarex’s UltiMAb technology, Medarex tells “The Pink Sheet” DAILY.
Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 1 of 3)
Hassan discusses how the $14.4 billion Organon acquisition benefits the company as well as other potential M&A areas of interest for Schering-Plough.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: